You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Developing a novel therapy for diabetic retinopathy

    SBC: EVERGLADES BIOPHARMA LLC            Topic: W

    Project Summary Diabetic retinopathy DR is a leading cause of vision loss affecting about million people worldwide A major breakthrough in DR therapy is the recent approval of vascular endothelial growth factor VEGF inhibitors However anti VEGF therapy has limited efficacy with a number of side effects The critical barrier is how to identify other angiogenic targets for alternative or ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. A Randomized Blinded Placebo Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell LMSC Therapy for Treating The Metabolic Syndrome

    SBC: Longeveron LLC            Topic: NIA

    The metabolic syndrome MetS is a cluster of factors that increases the risks for cardiovascular disease type diabetes mellitus and mortality and currently affects andgt of US adults MetS is associated with endothelial dysfunction decreased circulating endothelial progenitor cells EPCs and a pro inflammatory state We have made the exciting discovery that therapy with allogeneic me ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Inhibitors of PSMB and PSMB for the Treatment of Multiple Myeloma

    SBC: InhiProt            Topic: 103

    Multiple myeloma is incurable hematologic malignancy with an expected median survival of years The proteasome inhibitors bortezomib carfilzomib and the recently approved ixazomib are a mainstay of current myeloma treatment Despite an initial response rate approaching to proteasome inhibitor containing combinations all patients relapse and eventually become resistant to any treatments ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Development of PEGylated MTI for the treatment of relapsed Myeloma

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    ABSTRACT Modulation Therapeutics is developing a first in class cyclic peptide coined MTI for the treatment of multiple myeloma The company currently has a license for the parent molecule which has been awarded a patent covering the intellectual property for both composition of matter and use in cancer in the US and Europe Modulation Therapeutics is now poised to further advance this class ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Robust Predictor of Breast Cancer Risk

    SBC: Morgan and Mendel Genomics, Inc.            Topic: 103

    Summary Approximatelymillion women in the United States are at high risk for developing breast cancerbased on inheritance of a germline mutation in a gene in the double strand breakDSBrepair and cyclin checkpoint pathwaysMany are unaware of their genetic predispositionsbecause their family history is uninformative or unknownGenetic testing is important for identifying mutations in these genesbut i ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Probabilistic Modeling for Software Guided Radiotherapy Patient Plan QA

    SBC: SUN NUCLEAR CORP.            Topic: 103

    Errors in the planning and delivery of radiation therapy can result in inferior outcomes for patients The magnitude of this problem is now well appreciated from cooperative group trials and other sources At present however there are few concrete tools to reduce the chance of plan errors passing undetected Current practice uses a variety of error mitigation means such as human inspection of th ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. A single-cell device to capture and analyze rare T-cells from solid tumors.

    SBC: ISOPLEXIS CORPORATION            Topic: 102

    Checkpoint inhibitors towards targets such as PDand PD Lare being developed to activate quiescent T cells embedded in tumors and enable them to recruit the rest of the immune system to fight a cancer massHow these new cures reactivate the relatively few Tumor Infiltrating LymphocytesTILsenabling the release of a complex message of cytokines to recruit the immune systemthus impacting treatment effi ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Optimizing electrical impedance myography outcomes through data mining

    SBC: MYOLEX, INC.            Topic: NIAMS

    Project summary Electrical impedance myography EIM is a non invasive technology for the assessment of muscle that is based on the application of a weak high frequency electrical current to a muscle and the measurement of the resulting surface voltages The further development and application of EIM remains the main business focus of Skulpt Inc a small business concern based in Boston and San ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. A single-cell mouse proteomic system to accelerate pre-clinical immune therapeutics

    SBC: ISOPLEXIS CORPORATION            Topic: 100

    With this PhasesubmissionIsoPlexis proposes to deliver a single cell proteomic solution for ultra sensitive detection of unique correlative biomarkers in pre clinical mouse modelsin an automated system that can be used to accelerate the discovery of potential immune therapeuticsThe recent revolution in new basic science discovery is failing to translate into improved patient treatmentThe reduction ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Low Cost Catalytic Biomass Cookstove for Improved Indoor Air Quality

    SBC: MAINSTREAM ENGINEERING CORP            Topic: NIEHS

    Project Summary An estimated billion people or about one third of the world s population rely on biomass fuel for cooking Emissions from biomass cookstoves contribute to global climate change indoor local air quality issues and related health effects In particular indoor air quality issues related to biomass cookstoves contribute significantly to rates of acute respiratory infection Re ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government